All deliverables
Print · HCPs & Medical Affairs

Data Infographic.
Clinical evidence that lands before you say a word.

Audience
HCPs, medical affairs, conference
Format
A4/A3 single-sheet PDF
Speciality
Chart + Viz
Price from
£240

A single-sheet, publication-quality clinical data visualisation.

The Data Infographic is an A4 or A3 single-sheet document that communicates clinical trial data visually — trial results, comparative efficacy, subgroup analysis, or a full programme evidence summary. It is designed to be read at a conference poster stand, left on a desk, or included in an MLR submission pack.

Chart leads the data work: ingesting Aria's structured evidence package, selecting the right chart type for the data shape, and generating publication-quality SVG visualisations with full statistical accuracy. Bar charts start at zero. Confidence intervals are displayed. Comparative data includes appropriate caveats.

Viz designs the full A4/A3 page layout, integrating charts, copy, and brand elements into a coherent visual argument. Print-ready PDF at 300dpi, with bleed and safe zones, is the standard output.

The team behind it.

Core team shown. Complexity tier determines which additional specialists are activated.

Simple, Medium, or Complex — you choose the depth.

Simple Medium Complex
Scope 1 trial · 2 charts Comparative data · 3–4 charts + narrative Full evidence base · meta-analysis · subgroup waterfall
Team Sys, Aria, Chart, Viz, Pace + Medi + Reg
Price range ~£240 ~£460 ~£920
Best for Key trial results, congress handout Head-to-head comparison, multi-endpoint summary Full programme summary, KOL conference material

What it looks like.

VERIFY-1 Data Infographic (Simple)
Verixtol® — VERIFY-1 at a glance
72%
PASI 90 at week 16
vs 4% placebo (p<0.0001)
4.2wk
Median time to PASI 50
vs 14.7 weeks (placebo)
Study design
VERIFY-1: Phase III, randomised, double-blind, placebo-controlled trial. 312 adults with moderate-to-severe plaque psoriasis. Verixtol 150mg vs placebo for 16 weeks.
Comparative Infographic (Medium)
Verixtol® across the IL-17A class: comparative efficacy
PASI 90 at week 16 — indirect treatment comparison (ITC)4
Verixtol
72%
Ixekizumab
68%
Secukinumab
61%
ITC. Not a direct comparison. Interpret with caution. Data: Bard et al, JEADV 2025.4
VERIFY Programme — Conference Infographic (Complex)
Verixtol® — VERIFY Programme: Complete Evidence Summary
Four trials. 1,847 patients. Up to 3 years.
VERIFY-1 (Psoriasis)
72% PASI 90
Week 16, n=312
VERIFY-AXIA (axSpA)
58% ASAS40
Week 16, n=341
Subgroup analysis: PASI 90 by body weight (VERIFY-1)
Waterfall plot of individual patient responses shows consistent PASI 90 achievement across body weight quartiles (Q1–Q4), with no statistically significant interaction observed (interaction p=0.34). Response maintained in patients >100kg without dose adjustment.

Full rendered examples will be available at launch.

ABPI 2024 Compliance

Promotional Data Infographics are subject to ABPI 2024 review. Non-promotional medical education infographics are reviewed for factual accuracy and fair data presentation, but may not require full promotional compliance review.

Start your Data Infographic.

Tell us about your brief. We'll assemble the right team and get started today.

Start a project →